

Jeffrey G Suico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3043520/publications.pdf>

Version: 2024-02-01

23
papers

1,161
citations

840776

11
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

1127
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. <i>Diabetes Therapy</i> , 2020, 11, 1591-1603.	2.5	21
2	Nasal Glucagon Delivery is More Successful than Injectable Delivery: A Simulated Severe Hypoglycemia Rescue. <i>Endocrine Practice</i> , 2020, 26, 407-415.	2.1	23
3	Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 483-492.	2.3	5
4	13-LB: Nasal vs. Injected Glucagon: User Experience Results of a Simulated Severe Hypoglycemia Study. <i>Diabetes</i> , 2019, 68, .	0.6	3
5	Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 412-424.	2.0	2
6	Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S53.	0.8	1
7	Pharmacokinetics, pharmacodynamics and drug interactions of evacetrapib with select statins in healthy Chinese subjects. <i>International Journal of Pharmacokinetics</i> , 2018, 3, 69-80.	0.5	0
8	Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects. <i>Pharmacotherapy</i> , 2016, 36, 749-756.	2.6	4
9	GW27-e0479 Unexpected Effect of Evacetrapib on Simvastatin Pharmacokinetics in Healthy Chinese Subjects. <i>Journal of the American College of Cardiology</i> , 2016, 68, C129.	2.8	0
10	Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [¹³ C ₈]-evacetrapib as a tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 238-244.	1.0	14
11	Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 563-572.	1.9	0
12	Evacetrapib: <i>in vitro</i> and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00179.	2.4	9
13	A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 483-489.	2.0	7
14	CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1388-1398.	2.4	9
15	Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	31
16	Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1576-1585.	2.4	32
17	Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT/QTc Study in Healthy Participants. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 283-289.	2.0	10
18	LOINC, a Universal Standard for Identifying Laboratory Observations: A 5-Year Update. <i>Clinical Chemistry</i> , 2003, 49, 624-633.	3.2	433

#	ARTICLE	IF	CITATIONS
19	Electronic Laboratory Reporting: Barriers, Solutions and Findings. Journal of Public Health Management and Practice, 2001, 7, 60-66.	1.4	81
20	The Regenstrief Medical Record System: a quarter century experience. International Journal of Medical Informatics, 1999, 54, 225-253.	3.3	356
21	What is done, what is needed and what is realistic to expect from medical informatics standards. International Journal of Medical Informatics, 1998, 48, 5-12.	3.3	32
22	Behaviors predicting foot lesions in patients with non-insulin-dependent diabetes mellitus. Journal of General Internal Medicine, 1998, 13, 482-484.	2.6	18
23	Canopy Computing. JAMA - Journal of the American Medical Association, 1998, 280, 1325.	7.4	70